The state of Connecticut currently has 6 active clinical trials seeking participants for Endometriosis research studies. These trials are conducted in various cities, including New Haven, Hartford, Farmington and Stamford.
Pre-IVF Treatment With a GnRH Antagonist in Women With endometriosis_temp
NCT06375811
Recruiting
A Phase 3 clinical trial of oral GnRH antagonist pre-treatment for women with endometriosis who are undergoing IVF, with a primary outcome of live birth rate. The investigators' central hypothesis is that in infertile woman with endometriosis undergoing in vitro fertilization-embryo transfer (IVF-ET), live birth rates will improve in those pretreated with GnRH antagonist compared to those not pretreated with GnRH antagonist.
Gender:
Female
Ages:
Between 18 years and 40 years
Trial Updated:
04/16/2024
Locations: Yale School of Medicine Dept.of Ob/Gyn & Reproductive Sciences, New Haven, Connecticut
Conditions: Infertility, Endometriosis
Register for Updates
A Study to Investigate Efficacy and Safety of OG-6219 BID in 3 Dose Levels Compared With Placebo in Participants Aged 18 to 49 With Moderate to Severe Endometriosis-related Pain
NCT05560646
Recruiting
The purpose of this global Phase 2 study is to determine the efficacy, safety, and tolerability of 3 dose levels of OG-6219 in pre-menopausal women between 18 and 49 years of age (inclusive), who have moderate to severe endometriosis-related pain.
Gender:
Female
Ages:
Between 18 years and 49 years
Trial Updated:
02/22/2024
Locations: Yale Fertility Center, Orange, Connecticut
Conditions: Endometriosis
Register for Updates
Endometriosis and Microvascular Dysfunction; Simvastatin and Duavee
NCT05059626
Recruiting
Purpose: To determine the effects of SERM and simvastatin interventions on endothelial dysfunction in women with endometriosis. Hypothesis: Treatment with the SERM (bazedoxifene + conjugated estrogen) or with simvastatin will decrease systemic inflammation and improve specific measures of cardiovascular function including endothelium-dependent vasodilation.
Gender:
Female
Ages:
Between 18 years and 45 years
Trial Updated:
02/05/2024
Locations: The John B. Pierce Laboratory, New Haven, Connecticut
Conditions: Endometriosis
Register for Updates
Cardiovascular Disease Risk in Women With Endometriosis
NCT03746535
Recruiting
To test the hypothesis that estrogen suppression impairs endothelial dysfunction in endometriosis.
Gender:
Female
Ages:
Between 18 years and 45 years
Trial Updated:
08/16/2023
Locations: John B Pierce Laboratory, New Haven, Connecticut
Conditions: Endometriosis
Register for Updates
Cancer Driving Mutations in Endometriosis Lesions and Development of Progesterone Resistance
NCT03756480
Recruiting
This study will test the hypothesis that the molecular changes present in ectopic endometriosis lesions correlate with progesterone-resistant disease (using the criteria defined in this study) and are present in matched eutopic endometrium.
Gender:
Female
Ages:
Between 18 years and 45 years
Trial Updated:
08/07/2023
Locations: Yale School of Medicine, New Haven, Connecticut
Conditions: Endometriosis, Endometrial Diseases
Register for Updates
The EMPOWER Study: Endometriosis Diagnosis Using microRNA
NCT04598698
Recruiting
Endometriosis is a complex, heterogeneous disease that may present inconsistently across women. Using disease-specific biomarkers and advanced biostatistics, DotLab is developing a biomarker test to confirm the presence of endometriosis.This is a multi-center, prospective, observational, minimal risk study in women undergoing laparoscopy, laparotomy or other pelvic surgical procedure for endometriosis, infertility or another benign gynecological indication. Participants will undergo 2 study visi... Read More
Gender:
Female
Ages:
Between 18 years and 49 years
Trial Updated:
01/11/2022
Locations: Yale University, New Haven, Connecticut
Conditions: Endometriosis
Register for Updates